In postmenopausal women, this is most frequently with an aromatase inhibitor (AI) because these drugs have been shown to reduce mortality from BC by approximately 40%; nevertheless, reducing this further is a priority for contemporary research, as patients with ER + BC have a steady risk of recurrence for 15 years or more after treatment. This evidence concerns the gene CYP19A1 and breast cancer.